SITC Publishes First of its Kind Comprehensive Cancer Immunotherapy Textbook

June 2, 2017

MILWAUKEE – Today, the Society for Immunotherapy of Cancer (SITC) unveiled Cancer Immunotherapy Principles and Practice, an authoritative textbook covering all aspects of cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease. “There is so much excitement and movement in the field of cancer immunotherapy. While the SITC Primer and other educational efforts help people stay up to date, there is a real need in the field for a more comprehensive approach,” said SITC President, Lisa H. Butterfield, PhD, Professor of Medicine, University of Pittsburgh. “With this new textbook, leaders in the field have brought their wealth of experience to each chapter, covering the scientific foundations and the latest clinical data,” she added.

This wide-ranging reference work, edited by current (Lisa H. Butterfield, PhD) and past (Howard L. Kaufman, MD, FACS and Francesco M. Marincola, MD, FACS) presidents of SITC, covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation.

With the use of cancer immunotherapies increasing rapidly, the need for a textbook that presents the history of the field, basic science and current clinical applications is timely. Featuring five sections and more than 50 chapters covering basic principles of tumor immunology, cancer immunotherapy targets and classes, immune function in cancer patients, disease specific treatments and outcomes, and regulatory aspects of cancer immunotherapy, this textbook will be a valuable resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking to understand the basic science and clinical application of cancer immunotherapy.

Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject.

To order:

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.

# # #

Media Contact

Julie Frinzi, Director of Communications
(414) 271-2456